The Pharmaletter

One To Watch

immunitas-company

Immunitas Therapeutics

A clinical-stage precision immunotherapy company developing novel, differentiated therapeutics for patients with cancer.

The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT. Since its founding in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund.

Want to Update your Company's Profile?


More Immunitas Therapeutics news >